ASSESSMENT OF C-myc ONCOGENE AMPLIFICATION IN BREAST CANCER

Authors

  • M. MOAWAD Department of Pathology, National Cancer Institute, Cairo University
  • GHADA M. NASR Department of Molecular Diagnostics, Genetic Engineering and Biotechnology Research Institute (GEBRI), Sadat City University
  • R. A. SABER Branch of Biochemistry, Collage of Technology and Development, Zagazig University
  • DALIA ABOUL AZM Unit of Early Detection and Cancer Prevention, National Cancer Institute, Cairo University
  • A. M. FAHMY Department of Pathology, National Cancer Institute, Cairo University

Abstract

Allred D, J. Harvey and M. Berardo (1998). Prognostic and predictive factors in breast cancer by immunohisctochemnical analysis. Mod. Patho., 11: 155-168.
Bancroft, J. D. and M. Gamble (2002). Theory and Practice of Histological techniques, Fifth Edition; Elserviser Science Limited, 689- 691.
Berns, E. M., J. G. Klijn, I. L. van Staveren, H. Portengen, E. Noordegraaf and J. A. Foekens (1992). Prevalence of amplification of the oncogenes C-myc, HER2/neu, and int-2 in one thousand human breast tumors: correlation with steroid receptors. Europe- an Journal of Cancer, 28: 697-700.
Bieche, I., I. Laurendeau, S. Tozlu, M. Olivi, D. Vidaud, R. Lidereau and
M. Vidaud (1999). Quantitation of myc gene expression in sporadic breast tumors with a real-time reverse. Cancer Res., 59: 2759-2765.
Bolufer, P., R. Molina, A. Ruiz, M. Hernandez, C. Vazquez and A. Lluch (1994). Estradiol receptors in combination with neu or myc oncogene amplifications might define new subtypes of breast cancer. Clinica Chimica Acta, 229: 107-122.
Coombs, N. J., A. C. Gouph and J. N. Primrose (1999). Optimization of DNA and RNA extraction from archival formalin fixed tissue. Nucleic Acid Res., 27: 12-18.
El-Bolkainy, M., A. Noh, T. El-Bolkainy and M. O. Badawy (2013). Pathology of Cancer, 4th Edition. Medical bock library, Cairo, Egypt, 298- 299.
Grushko, T. A., J. J. Dignam, S. Das, A. M. Blackwood, C. M. Perou, Karin K. Ridderstrale, Kristin N. Anderson, M. J. Wei, A. J. Adams, F. G. Hagos, L. Sveen, H. T. Lynch, B. L. Weber and O. I. Olopade (2004). Myc is amplified in BRCA1- associated breast cancers. Clinical Cancer Research, 10: 499-507.
Lance, R. T. and P. T. William (2015). MYC and Chromatin. The open Access Journal of Science and Technology. Vol. 3, Article, ID 101124, 26 pages.
Liao, D. J. and R. B. Dickson (2000). C- myc in breast cancer. Endocrine-Related Cancer, 7: 143-164.
Lőnn, U., S. Lőnn, B. Nilsson and B. Stenkvist (1995). Prognostic value of C-erbB-2 and myc amplification in breast cancer imprints. Cancer, 75: 2681-2687.
Maniatis, T., E. F. Fritsch and J. Sambrook (1989). Molecular cloning: a laboratory manual. Cold Spring Harbor, cold spring Harbor laboratory.
Persons, D. L., K. A. Borelli and P. H. Hsu (1997). Quantitation of HER– 2/neu and C-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Modern Pathology, 10: 720-727.
Saunders, D. B. and G. R. Trapp (2001). Basic and clinical biostatistics, 3rd edition, Connecticut, Appleton & Lang.
Schreiber, G. and L. Dubeau (1990). C- myc Proto-oncogene amplification detected by polymerase chain reaction in archival human ovarian carcinomas. American Journal of Pathology, 3: 653-658.
Wolff, A., M. Hammond and J. Schwartz (2007). Oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Clin. Oncol., 25: 118-145.
Vural, C. H., N. Turaçlar, S. Elagöz and U. Ünsal (2014). Mutation analysis of C-myc gene family in patients with primary breast carcinoma in Turkey population. Scholarly Journal of Biological Science, 3: 25-31.

Downloads

Published

2019-04-13

Issue

Vol. 47 No. 2 (2018)

Section

Articles

Most read articles by the same author(s)